FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir

Thursday, October 22, 2020

Print this page Email A Friend!


CALIFORNIA, United States (AP)— US regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalised patients through an IV.

The drug, which California-based Gilead Sciences Inc is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the US National Institutes of Health.

It had been authorised for use on an emergency basis since spring, and now becomes the first drug to win full Food and Drug Administration approval for treating COVID-19. President Donald Trump received it when he was sickened earlier this month.

Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who are hospitalised for a coronavirus infection. For patients younger than 12, the FDA will still allow the drug's use in certain cases under its previous emergency authorisation.

The drug works by inhibiting a substance the virus uses to make copies of itself. Certain kidney and liver tests are required before starting patients on it to ensure it's safe for them and to monitor for any possible side effects. And the label warns against using it with the malaria drug hydroxychloroquine, because that can curb its effectiveness.

“We now have enough knowledge and a growing set of tools to help fight COVID-19,” Gilead's chief medical officer, Dr Merdad Parsey, said in a statement.

The drug is either approved or has temporary authorisation in about 50 countries, he noted.

Its price has been controversial, given that no studies have found it improves survival. Last week, a large study led by the World Health Organization found the drug did not help hospitalised COVID-19 patients, but that study did not include a placebo group and was less rigorous than previous ones that found a benefit. The FDA's approval statement noted that, besides the NIH-led one, two other studies found the drug beneficial.

Gilead charges US$2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and US$3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

So far, only steroids such as dexamethasone have been shown to cut the risk of dying of COVID-19. The FDA also has given emergency authorisation to using the blood of survivors, and two companies are currently seeking similar authorisation for experimental antibody drugs.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT